Overview

Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea

Status:
Completed
Trial end date:
2012-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to Evaluate the Optimal Dosage of Mosapride (Medirac) and Probitics in Irritable Bowel Syndrome Without Predominant Diarrhea.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Treatments:
Mosapride
Criteria
Inclusion Criteria:

- Aged 18-75 years who satisfied RomeIII criteria for the diagnosis of IBS

- Signed informed consent

Exclusion Criteria:

- IBS-D

- evidence of cathartic colon or history laxative abuse